- Home
- AUPH vs PGRE Comparison
AUPH vs PGRE Comparison
Compare AUPH & PGRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- PGRE
- Stock Information
- Founded
- AUPH 1993
- PGRE 1978
- Country
- AUPH Canada
- PGRE United States
- Employees
- AUPH N/A
- PGRE N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- PGRE Real Estate Investment Trusts
- Sector
- AUPH Health Care
- PGRE Real Estate
- Exchange
- AUPH Nasdaq
- PGRE Nasdaq
- Market Cap
- AUPH 1.4B
- PGRE 1.4B
- IPO Year
- AUPH 1999
- PGRE 2014
- Fundamental
- Price
- AUPH $12.22
- PGRE $7.24
- Analyst Decision
- AUPH Strong Buy
- PGRE Hold
- Analyst Count
- AUPH 4
- PGRE 4
- Target Price
- AUPH $12.25
- PGRE $5.55
- AVG Volume (30 Days)
- AUPH 1.7M
- PGRE 3.1M
- Earning Date
- AUPH 11-06-2025
- PGRE 10-29-2025
- Dividend Yield
- AUPH N/A
- PGRE N/A
- EPS Growth
- AUPH N/A
- PGRE N/A
- EPS
- AUPH 0.42
- PGRE N/A
- Revenue
- AUPH $260,111,000.00
- PGRE $701,980,000.00
- Revenue This Year
- AUPH $16.92
- PGRE $1.41
- Revenue Next Year
- AUPH $14.29
- PGRE N/A
- P/E Ratio
- AUPH $29.10
- PGRE N/A
- Revenue Growth
- AUPH 25.59
- PGRE 35.23
- 52 Week Low
- AUPH $6.42
- PGRE $3.75
- 52 Week High
- AUPH $12.82
- PGRE $7.55
- Technical
- Relative Strength Index (RSI)
- AUPH 61.79
- PGRE 61.26
- Support Level
- AUPH $11.57
- PGRE $6.58
- Resistance Level
- AUPH $12.82
- PGRE $7.55
- Average True Range (ATR)
- AUPH 0.36
- PGRE 0.20
- MACD
- AUPH -0.10
- PGRE 0.02
- Stochastic Oscillator
- AUPH 52.08
- PGRE 68.21
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.